TTM
$824M
YoY change
-2.7%
5Y CAGR
+6.9%
Peak year (FY2021)
$880M
Cumulative EBITDA
$9.73B
EBITDA history chart for West Pharmaceutical Services (WST) from 2016 to 2025
Latest: $724M
EBITDA growth chart for West Pharmaceutical Services (WST) from 2016 to 2025
Latest: -2.7%
EBITDA history table for West Pharmaceutical Services (WST) from 1985 to 2025
| FY2025 | $724M | -2.7% | -$20.2M | ||
| FY2024 | $744M | -11.9% | -$100M | ||
| FY2023 | $844M | +4.5% | +$36M | ||
| FY2022 | $808M | -8.1% | -$71.6M | ||
| FY2021 | $880M | +69.5% | +$361M | ||
| FY2020 | $519M | +28.7% | +$116M | ||
| FY2019 | $403M | +14.2% | +$50M | ||
| FY2018 | $353M | +8.3% | +$27M | ||
| FY2017 | $326M | +13.7% | +$39.3M | ||
| FY2016 | $287M | +31.8% | +$69.2M | ||
| FY2015 | $218M | -21.8% | -$60.8M | ||
| FY2014 | $279M | +10.4% | +$26.3M | ||
| FY2013 | $252M | +26.1% | +$52.2M | ||
| FY2012 | $200M | +9.1% | +$16.6M | ||
| FY2011 | $183M | +13.7% | +$22.1M | ||
| FY2010 | $161M | -3.1% | -$5.1M | ||
| FY2009 | $166M | -10.6% | -$19.7M | ||
| FY2008 | $186M | +18.2% | +$28.6M | ||
| FY2007 | $158M | +5.1% | +$7.6M | ||
| FY2006 | $150M | +22.0% | +$27M | ||
| FY2005 | $123M | +30.1% | +$28.4M | ||
| FY2004 | $94.5M | +11.4% | +$9.7M | ||
| FY2003 | $84.8M | +2.4% | +$2M | ||
| FY2002 | $82.8M | +10.8% | +$8.1M | ||
| FY2001 | $74.7M | -1.6% | -$1.2M | ||
| FY2000 | $75.9M | -25.7% | -$26.2M | ||
| FY1999 | $102M | +5.3% | +$5.1M | ||
| FY1998 | $97M | +3.4% | +$3.2M | ||
| FY1997 | $93.8M | +11.7% | +$9.8M | ||
| FY1996 | $84M | +7.8% | +$6.1M | ||
| FY1995 | $77.9M | +11.0% | +$7.7M | ||
| FY1994 | $70.2M | +11.3% | +$7.1M | ||
| FY1993 | $63.1M | -0.3% | -$200K | ||
| FY1992 | $63.3M | +172.8% | +$40.1M | ||
| FY1991 | $23.2M | -47.2% | -$20.7M | ||
| FY1990 | $43.9M | -22.2% | -$12.5M | ||
| FY1989 | $56.4M | +14.4% | +$7.1M | ||
| FY1988 | $49.3M | +5.6% | +$2.6M | ||
| FY1987 | $46.7M | +2.6% | +$1.2M | ||
| FY1986 | $45.5M | +28.2% | +$10M | ||
| FY1985 | $35.5M | — | — |
- FY2025$724M-2.7%
- FY2024$744M-11.9%
- FY2023$844M+4.5%
- FY2022$808M-8.1%
- FY2021$880M+69.5%
- FY2020$519M+28.7%
- FY2019$403M+14.2%
- FY2018$353M+8.3%
- FY2017$326M+13.7%
- FY2016$287M+31.8%
- FY2015$218M-21.8%
- FY2014$279M+10.4%
- FY2013$252M+26.1%
- FY2012$200M+9.1%
- FY2011$183M+13.7%
- FY2010$161M-3.1%
- FY2009$166M-10.6%
- FY2008$186M+18.2%
- FY2007$158M+5.1%
- FY2006$150M+22.0%
- FY2005$123M+30.1%
- FY2004$94.5M+11.4%
- FY2003$84.8M+2.4%
- FY2002$82.8M+10.8%
- FY2001$74.7M-1.6%
- FY2000$75.9M-25.7%
- FY1999$102M+5.3%
- FY1998$97M+3.4%
- FY1997$93.8M+11.7%
- FY1996$84M+7.8%
- FY1995$77.9M+11.0%
- FY1994$70.2M+11.3%
- FY1993$63.1M-0.3%
- FY1992$63.3M+172.8%
- FY1991$23.2M-47.2%
- FY1990$43.9M-22.2%
- FY1989$56.4M+14.4%
- FY1988$49.3M+5.6%
- FY1987$46.7M+2.6%
- FY1986$45.5M+28.2%
- FY1985$35.5M—
EBITDA values are taken from West Pharmaceutical Services's reported income statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About EBITDA at West Pharmaceutical Services (WST)
According to West Pharmaceutical Services's latest reported financial statements, the company's current EBITDA (TTM) is $824M. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a common proxy for operating cash generation that strips out non-cash charges (depreciation and amortization) and capital structure effects (interest, taxes). Useful for comparing companies with different leverage and asset bases — see operating income and net income for fully GAAP figures.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
In 2025, West Pharmaceutical Services (WST) EBITDA totalled $724M – edged down 2.7% year-over-year.
West Pharmaceutical Services EBITDA has grown on net over the period, with a +6.9% compound annual growth rate over 2020–2025 (5 years).
West Pharmaceutical Services EBITDA peaked at $880M in 2021; the latest annual figure is $724M in 2025 (17.7% below peak).
2021 marks the peak EBITDA at $880M, with the historical low of $23.2M recorded in 1991.
West Pharmaceutical Services EBITDA by Year
West Pharmaceutical Services EBITDA 2025: $724M
West Pharmaceutical Services EBITDA in 2025 was $724M, edged down 2.7% below 2024.
West Pharmaceutical Services EBITDA 2024: $744M
2024's EBITDA for West Pharmaceutical Services came in at $744M, declined 11.9% below 2023.
West Pharmaceutical Services EBITDA 2023: $844M
West Pharmaceutical Services posted EBITDA of $844M in 2023, edged up 4.5% from 2022.
West Pharmaceutical Services EBITDA 2022: $808M
In 2022, West Pharmaceutical Services reported EBITDA of $808M, declined 8.1% below 2021.
West Pharmaceutical Services EBITDA 2021: $880M
West Pharmaceutical Services EBITDA in 2021 was $880M.
See more financial history for West Pharmaceutical Services (WST).
Sector peers by EBITDA
Healthcare peers of West Pharmaceutical Services (WST), ranked by their latest EBITDA
| $41.1B | |
| $28.3B | |
| $27.9B | |
| $24.4B | |
| $23.1B | |
| $17.6B | |
| $16.9B | |
| $11.5B |
- $41.1B
- $28.3B
- $27.9B
- $24.4B
- $23.1B
- $17.6B
- $16.9B
Frequently asked questions
West Pharmaceutical Services (WST) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
- Buybacks2.34% TTM
- Dividend Profile0.32% yield
- Dividend Calculator
- Dividend Forecast
- Dividend Capture
- Stock Split History4 splits
How this company returns cash to shareholders — buybacks, dividends, and stock splits.